Preprint Article Version 1 This version is not peer-reviewed

Dabrafenib, a selective BRAFV600E inhibitor, is not able to reverse the CpG island methylator phenotype in RKO colorectal cell line

This preprint has been withdrawn.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.